- Home
- CHRD vs NUVL Comparison
CHRD vs NUVL Comparison
Compare CHRD & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRD
- NUVL
- Stock Information
- Founded
- CHRD 2007
- NUVL 2017
- Country
- CHRD United States
- NUVL United States
- Employees
- CHRD N/A
- NUVL N/A
- Industry
- CHRD Oil & Gas Production
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CHRD Energy
- NUVL Health Care
- Exchange
- CHRD Nasdaq
- NUVL Nasdaq
- Market Cap
- CHRD 6.5B
- NUVL 5.6B
- IPO Year
- CHRD 2010
- NUVL 2021
- Fundamental
- Price
- CHRD $94.43
- NUVL $71.64
- Analyst Decision
- CHRD Buy
- NUVL Strong Buy
- Analyst Count
- CHRD 12
- NUVL 9
- Target Price
- CHRD $157.17
- NUVL $113.44
- AVG Volume (30 Days)
- CHRD 1.1M
- NUVL 703.3K
- Earning Date
- CHRD 05-06-2025
- NUVL 05-08-2025
- Dividend Yield
- CHRD 8.68%
- NUVL N/A
- EPS Growth
- CHRD N/A
- NUVL N/A
- EPS
- CHRD 16.02
- NUVL N/A
- Revenue
- CHRD $4,917,685,000.00
- NUVL N/A
- Revenue This Year
- CHRD N/A
- NUVL N/A
- Revenue Next Year
- CHRD $1.14
- NUVL N/A
- P/E Ratio
- CHRD $5.89
- NUVL N/A
- Revenue Growth
- CHRD 35.23
- NUVL N/A
- 52 Week Low
- CHRD $79.83
- NUVL $55.54
- 52 Week High
- CHRD $188.02
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- CHRD 44.84
- NUVL 52.01
- Support Level
- CHRD $79.83
- NUVL $55.54
- Resistance Level
- CHRD $91.91
- NUVL $68.45
- Average True Range (ATR)
- CHRD 6.22
- NUVL 5.47
- MACD
- CHRD -0.47
- NUVL 0.75
- Stochastic Oscillator
- CHRD 42.95
- NUVL 93.01
About CHRD Chord Energy Corporation
Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.